**COUNTRY GENERAL INFORMATION** (World Bank, 2016)

- **Total population:** 3,719,300
- **Gender F/M (%):** 52.3 / 47.7
- **Population, age group <15/ ≥15 years (%):** 17.6 / 82.4
- **Life expectancy at birth (F/M, years) (2015):** 77.5 / 68.9
- **GDP (PPP int $):** 9,997
- **Income status:** Lower middle
- **Number of 2nd sub-national administrative level divisions, name:** 72, Municipality

### EPIDEMIOLOGY

**Endemicity status:**

<table>
<thead>
<tr>
<th></th>
<th>VL</th>
<th>CL</th>
<th>PKDL</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endemic status</td>
<td>Endemic</td>
<td>Endemic</td>
<td>Non endemic</td>
<td>Non endemic</td>
</tr>
</tbody>
</table>

- **Number of new cases (incidence):**
  - VL: 52
  - CL: 0
  - PKDL: N/A
  - MCL: N/A

- **Imported cases (%):**
  - VL: 3.6%
  - CL: 0%
  - PKDL: N/A
  - MCL: N/A

- **Gender distribution (%):**
  - VL: 54%
  - CL: N/A
  - PKDL: N/A
  - MCL: N/A

- **Age group distribution (%):**
  - VL: (62/10/29)
  - CL: (0/0/0)
  - PKDL: N/A
  - MCL: N/A

- **Incidence rate (cases/10,000 population in endemic areas):**
  - VL: 0.19
  - CL: 0.00
  - PKDL: N/A
  - MCL: N/A

- **Number of endemic 2nd sub-national administrative level divisions:**
  - VL: 28
  - CL: 24
  - PKDL: N/A
  - MCL: N/A

- **Population at risk (% at risk/total population):**
  - VL: 70%
  - CL: 55%
  - PKDL: N/A
  - MCL: N/A

- **Was there any outbreak?**
  - VL: No
  - CL: No
  - PKDL: N/A
  - MCL: N/A

- **Number of new foci:**
  - VL: No data
  - CL: 0
  - PKDL: N/A
  - MCL: N/A

**N/A = Not applicable; **Sociodemographic information (gender and age distribution) was provided for new cases.** Relapse in this country is defined as:** For VL “Recurrence of clinical signs or symptoms of VL with parasitological confirmation, after initial or clinical cure” and For CL “Recurrence of skin lesion on the same location confirmed by parasitological investigation after completion of treatment” ; **3 In Georgia, all districts where leishmaniasis is registered are endemic, except Zestafoni, Martvili, Sachkhere districts and Batumi city in Western Georgia.** Defined as “Number of people living in 2nd sub-national administrative level endemic areas”; **4 Defined as “In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever”.

#### Monthly distribution of new cases (January-December)

<table>
<thead>
<tr>
<th></th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>VL</td>
<td>7</td>
<td>8</td>
<td>3</td>
<td>7</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>CL</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis**

---

**Visceral leishmaniasis**

**Cutaneous leishmaniasis**

---

**Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2016**

---

**Visceral leishmaniasis**

**Cutaneous leishmaniasis**
### Disease distribution of new VL and CL cases at municipality level per 10,000 population (2016)

#### Visceral leishmaniasis

**VL incidence (per 10,000)**
- 0 case reported
- <1
- 1-4
- 5-9
- 10-19
- 20-49
- 50-99
- 100+ (N/A)

#### Cutaneous leishmaniasis

**CL incidence (per 10,000)**
- 0 case reported
- <1
- 1-4
- 5-9
- 10-19
- 20-49
- 50-99
- 100+ (N/A)

### CONTROL AND SURVEILLANCE

- **National Control Programme (LNCP) established:** No LNCP
- **Type of surveillance:** Integrated
- **Type of insecticide used for Indoor residual Spraying (IRS):** Synthetic pyrethroids
- **Year latest national guidelines:** 2009
- **Is leishmaniasis notifiable (mandatory report)?** Yes
- **Number of leishmaniasis health facilities:** 51

### DIAGNOSIS

<table>
<thead>
<tr>
<th></th>
<th>VL (%)</th>
<th>CL (%)</th>
<th>PKDL (%)</th>
<th>MCL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of people screened actively for:</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of people screened passively for:</td>
<td>355</td>
<td>25</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Cases diagnosed by RDT* (%: # RDT+/total VL cases):</td>
<td>79% (41/52)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of positive RDT* (%: # RDT+/total RDT):</td>
<td>12% (41/355)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Cases diagnosed by direct exam* (%: # slides+/total cases):</td>
<td>31% (16/52)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of positive slides* (%: # slides+/total slides):</td>
<td>47% (16/34)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Cases diagnosed clinically* (%: # clinical cases/total cases):</td>
<td>0% (0/52)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of CL cases with lesions equal to or greater than 4cm*:</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Proportion of CL cases with 4 or more lesions* (%: # CL cases/total CL cases):</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Percentage of cases with HIV coinfection*:</td>
<td>6% (3/52)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**N/A** = Not applicable; **RDT** = rapid diagnostic test; **HIV** = human immunodeficiency virus.

### TREATMENT AND MEDICINES

- **Is treatment provided for free in the public sector?** Yes
- **Antileishmanial medicines included in the National Medicine List:** Meglumine antimoniate

#### TREATMENT OUTCOME

<table>
<thead>
<tr>
<th></th>
<th>VL (%)</th>
<th>CL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of cases treated* (%: # treated cases/total cases):</td>
<td>100% (52/52)</td>
<td>N/A (0/0)</td>
</tr>
<tr>
<td>Initial cure rate* (%: # cases initially cured/total cases):</td>
<td>94% (49/52)</td>
<td>N/A (0/0)</td>
</tr>
<tr>
<td>Failure rate* (%: # patients with treatment failure/total cases):</td>
<td>0% (0/52)</td>
<td>N/A (0/0)</td>
</tr>
<tr>
<td>Case fatality rate* (%: # patients who died/total cases):</td>
<td>6% (3/52)</td>
<td>N/A (0/0)</td>
</tr>
</tbody>
</table>

**VL** = visceral leishmaniasis; **CL** = cutaneous leishmaniasis; **PKDL** = post-kala-azar dermal leishmaniasis; **MCL** = mucocutaneous leishmaniasis

*Failure in this country is defined as: “clinical signs and laboratory findings do not improve or worsen by the end of treatment course”

*These indicators only apply to new cases.